Tyra Biosciences (NASDAQ:TYRA) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04), Zacks reports.

Tyra Biosciences Price Performance

Shares of Tyra Biosciences stock opened at $32.53 on Wednesday. Tyra Biosciences has a 1-year low of $9.96 and a 1-year high of $40.65. The company has a market capitalization of $1.93 billion, a PE ratio of -14.92 and a beta of 0.77. The business has a 50-day moving average of $30.45 and a 200-day moving average of $32.74.

Get Tyra Biosciences alerts:

Institutional Trading of Tyra Biosciences

Hedge funds have recently made changes to their positions in the stock. Millennium Management LLC raised its holdings in Tyra Biosciences by 28.2% in the first quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock valued at $3,759,000 after acquiring an additional 89,024 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Tyra Biosciences by 21.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock worth $725,000 after purchasing an additional 13,896 shares during the last quarter. Woodline Partners LP acquired a new stake in shares of Tyra Biosciences in the 1st quarter valued at about $931,000. Jane Street Group LLC bought a new position in shares of Tyra Biosciences during the first quarter worth about $324,000. Finally, Geode Capital Management LLC lifted its position in shares of Tyra Biosciences by 9.8% during the second quarter. Geode Capital Management LLC now owns 567,126 shares of the company’s stock worth $5,428,000 after purchasing an additional 50,836 shares during the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Wolfe Research initiated coverage on shares of Tyra Biosciences in a research note on Tuesday, May 19th. They set a “peer perform” rating on the stock. JonesTrading began coverage on shares of Tyra Biosciences in a research note on Wednesday, June 17th. They set a “buy” rating and a $56.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of Tyra Biosciences in a research report on Thursday, May 14th. Guggenheim began coverage on shares of Tyra Biosciences in a research note on Tuesday, April 14th. They issued a “buy” rating and a $54.00 target price for the company. Finally, Bank of America boosted their price target on Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Tyra Biosciences has an average rating of “Moderate Buy” and an average price target of $47.00.

Get Our Latest Research Report on TYRA

About Tyra Biosciences

(Get Free Report)

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.

Featured Articles

• Five stocks we like better than Tyra Biosciences
• Visa’s BioCatch Deal Could Make Fraud Prevention a Bigger Business
• Caterpillar’s Record Quarter May Have Reset the Stock’s Ceiling
• The Real Reason Amazon Hit a $3 Trillion Valuation
• System Upgrade: First Internet Bancorp Options Surge

Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.